BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Taru MG, Neamti L, Taru V, Procopciuc LM, Procopet B, Lupsor-Platon M. How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography-A Review of the Literature and Proposed Multistep Approach. Diagnostics (Basel) 2023;13. [PMID: 36832276 DOI: 10.3390/diagnostics13040788] [Reference Citation Analysis]
2 Clayton-Chubb D, Kemp W, Majeed A, Lubel JS, Hodge A, Roberts SK. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023;15. [PMID: 36771394 DOI: 10.3390/nu15030687] [Reference Citation Analysis]
3 Kuznetsova AS, Dolgushina AI, Kudrinskaya YI, Selyanina AA, Khusainova GM, Genkel VV. Dynamic changes in the liver fibrosis marker FIB-4 as a predictor of adverse cardiovascular events in patients with high and very high cardiovascular risk. jour 2023. [DOI: 10.31146/1682-8658-ecg-206-10-43-49] [Reference Citation Analysis]
4 Armandi A, Rosso C, Younes R, Leeming DJ, Karsdal MA, Caviglia GP, Pérez-Diaz-Del-Campo N, D'Amato D, Abdulle A, Nicolosi A, Castelnuovo G, Saracco GM, Ribaldone DG, Bugianesi E. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2023;12. [PMID: 36675579 DOI: 10.3390/jcm12020650] [Reference Citation Analysis]
5 Choi SW, Kweon SS, Lee YH, Ryu SY, Nam HS, Shin MH. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study. PLoS One 2022;17:e0277729. [PMID: 36512564 DOI: 10.1371/journal.pone.0277729] [Reference Citation Analysis]
6 Josloff K, Beiriger J, Khan A, Gawel RJ, Kirby RS, Kendrick AD, Rao AK, Wang RX, Schafer MM, Pearce ME, Chauhan K, Shah YB, Marhefka GD, Halegoua-DeMarzio D. Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. J Cardiovasc Dev Dis 2022;9. [PMID: 36547416 DOI: 10.3390/jcdd9120419] [Reference Citation Analysis]
7 Gorban VV, Matveeva EV, Gorban EV, Kameneva ES. The possibilities of transabdominal sonographic diagnosis of liver and intestinal lesions in comorbid gastroesophageal reflux disease. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-134-143] [Reference Citation Analysis]
8 Eshraghian A, Fattahi MR, Taghavi A, Shamsaeefar A, Mansoorian M, Kazemi K, Nikeghbalian S, Malek-Hosseini SA. Metabolic syndrome, hepatic fibrosis, and steatosis diagnosed by liver stiffness measurement and controlled attenuation parameter after liver transplantation: the impact on long-term survival. Expert Rev Gastroenterol Hepatol 2022;16:1003-9. [PMID: 36254767 DOI: 10.1080/17474124.2022.2137488] [Reference Citation Analysis]
9 Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, Koch D, Gebregziabher M. The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. J Gen Intern Med 2022;37:3266-74. [PMID: 35048297 DOI: 10.1007/s11606-021-07341-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xu Q, Zhang X, Li H, Tian X, Zuo Y, Zhang Y, Zhang X, Wang Y, Wang A, Meng X. Aspartate aminotransferase to alanine aminotransferase ratio and clinical outcomes after acute ischemic stroke: the CNSR-III registry. Intern Emerg Med 2022;17:1987-96. [PMID: 35986833 DOI: 10.1007/s11739-022-03059-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cunha-silva M, Torres LD, Fernandes MF, Secundo TDML, Moreira MC, Yamanaka A, Monici LT, Costa LBED, Mazo DF, Sevá-pereira T. Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease. Gastroenterología y Hepatología (English Edition) 2022;45:579-584. [DOI: 10.1016/j.gastre.2021.12.005] [Reference Citation Analysis]
12 Salgado Alvarez GA, Pinto Galvez SM, Garcia Mora U, Cano Contreras AD, Durán Rosas C, Priego-Parra BA, Triana Romero A, Amieva Balmori M, Roesch Dietlen F, Martinez Vazquez SE, Mendez Guerrero IO, Chi-Cervera LA, Bernal Reyes R, Martinez Roriguez LA, Icaza Chavez ME, Remes Troche JM. Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease. World J Hepatol 2022;14:1633-42. [PMID: 36157869 DOI: 10.4254/wjh.v14.i8.1633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zeng Y, He H, An Z. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. Dis Markers 2022;2022:1254014. [PMID: 35811662 DOI: 10.1155/2022/1254014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Watanabe K, Takakubo N, Saigusa T, Nagasawa A, Yamana M, Ojima M, Kameda W, Susa S, Ishizawa K, Hisamitsu I, Duprez D. Fibrosis-4 Index Is Closely Associated with Arterial Damage and Future Risk of Coronary Heart Disease in Type 2 Diabetes. International Journal of Hypertension 2022;2022:1-8. [DOI: 10.1155/2022/2760027] [Reference Citation Analysis]
15 Lonardo A. Precision medicine in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2022;37:1175-8. [PMID: 35801994 DOI: 10.1111/jgh.15850] [Reference Citation Analysis]
16 Jagannathan R, Fiorentino TV, Marini MA, Sesti G, Bergman M. One-hour post-load glucose is associated with severity of hepatic fibrosis Risk. Diabetes Res Clin Pract 2022;189:109977. [PMID: 35772586 DOI: 10.1016/j.diabres.2022.109977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hameed S, Ur Rehman A, Massey S, Syed N, Anwar F, Ahmed D, Ahmad S. Grevillea robusta Delayed the Progression of Experimentally Induced Hepatic Fibrosis and Cirrhosis in Wistar Rats by Attenuating the Expression of Smooth Muscle Actin, Collagen, and TGF-β. Front Pharmacol 2022;13:904584. [DOI: 10.3389/fphar.2022.904584] [Reference Citation Analysis]
18 Haam J, Lee YK, Suh E, Kim Y. Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. Diagnostics 2022;12:1199. [DOI: 10.3390/diagnostics12051199] [Reference Citation Analysis]
19 Lavynenko O, Abdul-Ghani M, Alatrach M, Puckett C, Adams J, Abdelgani S, Alkhouri N, Triplitt C, Clarke GD, Vasquez JA, Li J, Cersosimo E, Gastaldelli A, DeFronzo RA. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes Metab 2022;24:899-907. [PMID: 35014145 DOI: 10.1111/dom.14650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Alalwani J, Eljazzar S, Basil M, Tayyem R. The impact of health status, diet and lifestyle on non‐alcoholic fatty liver disease: Narrative review. Clinical Obesity. [DOI: 10.1111/cob.12525] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Segura-Azuara NLÁ, Varela-Chinchilla CD, Trinidad-Calderón PA. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Front Med (Lausanne) 2021;8:774079. [PMID: 35096868 DOI: 10.3389/fmed.2021.774079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Mirashrafi S, Kafeshani M, Hassanzadeh A, Entezari MH. Is any association between alternate healthy eating index (AHEI) with lipid profile and liver enzymes? A cross-sectional Study. J Diabetes Metab Disord 2021;20:1537-44. [PMID: 34900806 DOI: 10.1007/s40200-021-00898-w] [Reference Citation Analysis]
23 Wang H, Wu J, Yang X, Liu J, Tao W, Hao Z, Wu B, Liu M, Zhang S, Wang D. Liver fibrosis indices associated with substantial hematoma expansion in Chinese patients with primary intracerebral hemorrhage. BMC Neurol 2021;21:478. [PMID: 34879856 DOI: 10.1186/s12883-021-02494-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. Ann Med 2021;53:1065-73. [PMID: 34184611 DOI: 10.1080/07853890.2021.1943514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Alqahtani SA, Schattenberg JM. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34346799 DOI: 10.1080/14737159.2021.1964958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Chen CC, Hsu WC, Wu HM, Wang JY, Yang PY, Lin IC. Association between the Severity of Nonalcoholic Fatty Liver Disease and the Risk of Coronary Artery Calcification. Medicina (Kaunas) 2021;57:807. [PMID: 34441013 DOI: 10.3390/medicina57080807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 De Matteis C, Cariello M, Graziano G, Battaglia S, Suppressa P, Piazzolla G, Sabbà C, Moschetta A. AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. Sci Rep 2021;11:14834. [PMID: 34290320 DOI: 10.1038/s41598-021-94277-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
29 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
30 Kotoku K, Michishita R, Matsuda T, Kawakami S, Morito N, Uehara Y, Higaki Y. The Association between Decreased Kidney Function and FIB-4 Index Value, as Indirect Liver Fibrosis Indicator, in Middle-Aged and Older Subjects. Int J Environ Res Public Health 2021;18:6980. [PMID: 34209974 DOI: 10.3390/ijerph18136980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Alqahtani SA, Broering DC, Alghamdi SA, Bzeizi KI, Alhusseini N, Alabbad SI, Albenmousa A, Alfaris N, Abaalkhail F, Al-Hamoudi WK. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:245. [PMID: 34074270 DOI: 10.1186/s12876-021-01828-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Besutti G, Bonilauri L, Manicardi E, Venturelli F, Bonelli E, Monelli F, Manicardi V, Valenti L, Ligabue G, Schianchi S, Massari M, Riva N, Froio E, Tagliavini E, Pattacini P, Giorgi Rossi P. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. Diabetes Res Clin Pract 2021;177:108882. [PMID: 34082056 DOI: 10.1016/j.diabres.2021.108882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Miyoshi T, Hamaguchi M, Kitagawa N, Hashimoto Y, Fukui M. Correlation between Liver Stiffness by Two-Dimensional Shear Wave Elastography and Waist Circumference in Japanese Local Citizens with Abdominal Obesity. J Clin Med 2021;10:1971. [PMID: 34064337 DOI: 10.3390/jcm10091971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
36 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]